What guidance did Akebia Therapeutics's management provide for the next earnings period?

What is Akebia Therapeutics's gross profit margin?

What is Akebia Therapeutics's latest dividend and current dividend yield?

What were the key takeaways from Akebia Therapeutics’s earnings call?

Did Akebia Therapeutics beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Akebia Therapeutics next quarter?

What were the key takeaways from Akebia Therapeutics's earnings call?

What is the revenue and EPS growth rate for Akebia Therapeutics year over year?

- **Vafseo Momentum**: 2025 net revenue of $45.8 million, with Q4 demand stabilizing at $11 million amid adherence challenges. 
- **Adherence Improvement**: Q1 2026 first refill rate of 87% (vs. 75% in 2025) for observed dosing patients. 
- **Pipeline Expansion**: Rare kidney disease assets (praliciguat, AKB-097, AKB-9090) advancing into Phase II/III trials. 
- **Financial Strength**: $184.8 million cash balance, with Auryxia revenue expected to decline in 2026 due to generics.

**【CEO Summary】**
- Vafseo generated $45.8 million in net product revenue in 2025, with Q4 demand of $11 million despite challenges in the second half. 
- Over 1,000 prescribers at 24 dialysis organizations have prescribed Vafseo, with 290,000 patients having access. 
- Q4 saw 128 new prescribers, and 25% of new patients came from non-USRC clinics. 
- Adherence rates improved to 87% in Q1 2026 for observed dosing patients, up from 75% in 2025. 
- Upcoming trials include VOCAL (Q4 2026) and VOICE (Q1 2027) to demonstrate clinical benefits vs. ESAs. 
- Rare kidney disease pipeline includes praliciguat (Phase II for FSGS), AKB-097 (Phase II basket trial for nephropathies), and AKB-9090 (Phase I for acute kidney injury). 

**【CFO Financial Commentary】**
- Total 2025 net product revenue: $227 million (Vafseo: $45.8M, Auryxia: $181.5M). 
- Q4 2025 net loss: $12.2 million vs. $22.8M in Q4 2024, driven by higher revenues and cost control. 
- Cash balance: $184.8 million as of Q4 2025, sufficient for 2+ years of operations. 
- Auryxia revenue expected to decline in 2026 due to generic competition. 
- R&D expenses: $62.4 million in 2025 (up 65% vs. 2024) for Vafseo trials and pipeline expansion. 

**【Q&A Highlights】**
- **Vafseo Growth**: Sequential demand growth expected in 2026, with Q4 2025 demand flat at $11 million. 
- **Adherence**: First refill rate improved to 87% in Q1 2026 (vs. 75% in 2025), driven by observed dosing protocols. 
- **DaVita Adoption**: Vafseo available at >30,000 home dialysis patients, with observed dosing protocols being implemented. 
- **Pipeline Updates**: AKB-097 Phase II basket trial to start H2 2026; AKB-9090 Phase I in healthy volunteers expected Q2 2026. 
- **R&D Day (April 2)**: Focus on praliciguat (FSGS), AKB-097 (nephropathies), and AKB-9090 (acute kidney injury).

Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript

- **Vafseo launch momentum**: $14.3M revenue in Q3, 70,000+ patients with access, but adherence challenges persist.
- **Clinical differentiation**: Win-Odds data shows 32% lower mortality/hospitalization risk vs. ESAs.
- **Financial strength**: $58.8M total revenue, $166.4M cash, supporting 2026 expansion.
- **Operational progress**: DaVita full rollout, USRC protocol adjustments, and 2027 data catalysts.

**【CEO Summary Section】**
- Vafseo generated $14.3 million in revenue in Q3, with 41 weeks of launch showing strong prescriber reception but operational challenges in dialysis settings.
- Positive clinical data from the Win-Odds analysis showed a 32% lower risk of death or hospitalization compared to ESAs, driving prescriber confidence.
- Long-term goal is to make Vafseo standard of care, with 70,000 patients gaining access by Q3 end, including DaVita's 200,000-patient rollout.

**【CFO Financial Commentary】**
- Total revenue $58.8 million (up 57% YoY), driven by Vafseo ($14.3M) and Auryxia ($42.5M).
- Net income $540,000 vs. $20M loss YoY, with cost reductions from amortization end and strong Auryxia performance.
- Cash position $166.4 million, supporting launch and pipeline.

**【Q&A Highlights】**
- Adherence challenges due to anemia manager protocols; retraining and titration strategies improving refill rates.
- DaVita pilot success led to full rollout, while USRC shifting to 300mg tablets for TIW dosing.
- VOICE and VOCAL studies to provide 2027 catalysts for long-term growth.


Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript

- **Vafseo Growth Accelerates**: Q2 revenue up 55% to $13.3M, with DaVita pilot targeting 275,000+ patients by Q4.
- **Clinical Evidence Building**: VOICE trial enrollment complete; VOCAL study explores red blood cell benefits.
- **Financial Strength**: $60.5M net product revenue, $137.3M cash, and 19% Auryxia sales growth despite generics.
- **Key Metrics**: 28% dose increase, 80%+ adherence, and 20% Medicare Advantage coverage driving adoption.

**【CEO Summary Section】**
- **Vafseo Launch Progress**: Q2 revenue of $13.3 million, up 55% from Q1, driven by U.S. Renal Care (USRC) and expanding access to 75,000+ patients by Q3. DaVita pilot begins in August, targeting 275,000+ patients by Q4.
- **Clinical Trial Momentum**: VOICE trial (all-cause mortality/hospitalization) fully enrolled (2,100+ patients) and VOCAL study (red blood cell characteristics) underway. FDA Type B meeting confirms ESA comparator for VALOR trial in non-dialysis CKD.
- **Revenue Milestone**: Total net product revenue of $60.5 million, highest in company history, supported by Auryxia sales growth despite authorized generic.

**【CFO Financial Commentary】**
- **Q2 Financials**: Net product revenue $60.5 million (vs. $41.2 million YoY), driven by Vafseo ($13.3M) and Auryxia ($47.2M). COGS down 42% to $9.9M due to R&D expense deferral. Net income $247,000 vs. loss of $8.6M YoY. Cash balance $137.3M, sufficient for pipeline expansion.
- **Auryxia Resilience**: 19% YoY growth despite generic risk, benefiting from Medicare bundle access improvements.

**【Q&A Highlights】**
- **Patient Segmentation**: 12% of scripts for home dialysis (PD) patients, aligning with market trends. Medicare Advantage coverage now 20% of prescriptions, up from fee-for-service dominance.
- **Dose Trends**: Average refill dose up 28% from 300mg starting dose, reflecting physician confidence in titration.
- **DaVita Timeline**: Pilot starts mid-August, expected to expand to full network by mid-November. Fresenius likely to follow similar pilot approach.
- **VALOR Trial**: Targeting 1,500 U.S. patients with ESA comparator; enrollment feasibility under review for 2025H2 start.
- **Generic Risk**: Auryxia sales growth despite 1 authorized generic; conservative financial planning for potential competition.

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

- **Vafseo Launch Exceeds Expectations**: $12 million Q1 revenue vs. $10-11 million guidance, driven by small/mid dialysis orgs. 
- **Clinical Trial Progress**: VOICE study 75% enrolled; VALOR trial for non-dialysis patients on track for H2 2025. 
- **Financial Strength**: 76% revenue growth to $57.3 million; net income turns positive to $6.1 million. 
- **LDO Expansion**: Q3 pilot to double patient access; 80/20 reimbursement split favorable. 
- **NDD Market Opportunity**: $10,000+ annual revenue potential in 550,000-patient non-dialysis CKD market.

**【CEO Summary Section】**
- **Vafseo Launch Success**: US net product revenues reached $12 million in Q1, exceeding guidance of $10-11 million. The launch is driven by small to mid-sized dialysis organizations (150,000 patients), with top five LDOs ordering the product. One LDO plans a pilot in Q3, while another allows exceptions. 
- **Clinical Momentum**: The VOICE study is 75% enrolled (2,200 subjects), targeting anemia treatment benefits. The Phase III VALOR trial for non-dialysis CKD patients is on track to start in H2 2025. 
- **Pipeline Expansion**: Akebia aims to advance multiple HIF-PH inhibitors into clinical trials in 2025.

**【CFO Financial Commentary】**
- **Revenue Growth**: Total revenue rose 76% YoY to $57.3 million, driven by Vafseo ($12 million) and Auryxia ($43.8 million). Auryxia faces generic competition but maintained strong Q1 sales. 
- **Cost Efficiency**: Cost of goods sold decreased 35% YoY to $7.6 million. R&D and SG&A expenses remained stable at $9.8 million and $25.7 million, respectively. 
- **Financial Health**: Net income improved to $6.1 million (vs. $18 million loss YoY). Cash reserves reached $113.4 million after a $46 million equity offering.

**【Q&A Highlights】**
- **LDO Rollout**: The first LDO pilot in Q3 aims to double patient access. Prescribers are seeing hemoglobin stability and ease of use. 
- **Reimbursement**: 80% of prescriptions are Medicare Fee-for-Service, with 20% covered by Medicare Advantage plans. 
- **Dose Titration**: Refills show dose increases, aligning with clinical trial data. 
- **NDD Market Potential**: The non-dialysis CKD market (550,000 patients) offers a $10,000+ per patient annual revenue opportunity.

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

- **Vafseo launch outperforms expectations**: $10-11M Q1 revenue vs. analyst estimates, driven by 500+ prescribers.
- **Auryxia decline offsets growth**: Q4 revenue down 19% YoY due to volume drop, but cash position strengthened with $18.4M ATM proceeds.
- **Focus on non-dialysis expansion**: FDA meeting to accelerate VALOR study for non-dialysis patients, targeting H2 2025 start.
- **Operational challenges remain**: Large dialysis orgs slow to operationalize protocols, but small/mid orgs driving early growth.


**【CEO Summary Section】**
- Vafseo Q1 2025 net product revenue expected to be $10-11 million, significantly ahead of analyst estimates.
- Early launch success driven by 500+ prescribers with average 8 prescriptions each, including 64 prescriptions from top prescribers.
- Focus on becoming standard of care for CKD anemia through dialysis launch and non-dialysis patient approval.

**【CFO Financial Commentary】**
- Total Q4 2024 revenue $46.5 million, down 19% YoY due to Auryxia volume decline.
- Auryxia net product revenue $44.4 million, down 17% YoY.
- R&D expenses $11.8 million (up 19% QoQ), SG&A $27.7 million (up 9% QoQ) due to Vafseo launch costs.
- Net loss $22.8 million vs. $0.6 million YoY; cash balance $51.9 million, strengthened by $18.4M ATM proceeds.

**【Q&A Key Points】**
- Q1 Vafseo revenue includes minor inventory build but no stocking impact.
- Dose frequency: 80% QD, 20% TIW; protocolization at large dialysis orgs lagging due to operational complexity.
- VALOR study for non-dialysis patients to start H2 2025; FDA meeting to align on study design and analysis plan.
- Medicare Advantage coverage for Vafseo at 15% of prescriptions, up from 0% pre-launch.
- Gross to net margin expected to decline as volume-based discounts kick in.


Actual										-0.47	-1.28	-0.42	-0.6	-0.45	-0.51	-0.34	-0.4	-0.35	0.15	-0.28	-0.04	-0.14	-0.06	-0.08	0	-0.09	-0.04	-0.1	-0.1	0.03	0	0	-0.05
Forecast										-0.6188	-0.48	-0.1688	-0.3971	-0.3688	-0.3391	-0.32	-0.305	-0.2869	-0.3233	-0.17	-0.1833	-0.145	-0.025	-0.085	-0.0383	-0.072	-0.0723	-0.0633	-0.0807	-0.038	-0.0153	-0.0108	-0.036
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+24.05%	-166.67%	-148.82%	-51.10%	-22.02%	-50.40%	-6.25%	-31.15%	-21.99%	+146.40%	-64.71%	+78.18%	+3.45%	-140.00%	+5.88%	+100.00%	-25.00%	+44.67%	-57.98%	-23.92%	+178.95%	+100.00%	+100.00%	-38.89%

AKBA

AKBA fundamentals

AKBA Q4 2025 Earnings

Earnings Call

You can ask Aime

AKBA

AKBA fundamentals

AKBA Q4 2025 Earnings

Earnings Call

AKBA Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

AKBA Earnings Call Summary for Q3/20258:00 AM on Nov 10, 2025

AKBA Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

AKBA Earnings Call Summary for Q1/20258:00 AM on May 8, 2025

AKBA Earnings Call Summary for Q4/20248:00 AM on Mar 13, 2025

You can ask Aime